North America Laboratory Survey Data for Drug Testing in Drug Impaired Driving and Traffic Fatality Investigations.

In 2004, the National Safety Council's Alcohol, Drugs and Impairment Division (NSC-ADID) set out to provide guidance for the standardization of laboratory testing practices in driving under the influence of drugs (DUID) and fatal motor vehicle crash investigations after identifying a lack of consistency in testing practices in this type of casework. A survey about laboratory testing practices, scopes of testing, and cutoffs was created using SurveyMonkey®, an online survey instrument, and sent to laboratories throughout the United States and Canada. Based on analysis of survey results and discussion, the first set of recommendations was published in 2007 with recommended scope and cutoffs for drug screening and confirmation in blood and urine. Subsequent surveys were sent to laboratories in 2012, 2016, and 2020, followed by updates to the recommendations published in 2013, 2017, and 2021. This publication highlights the 2024 survey results in addition to trends in drug testing practices and drug use positivity. With each survey year, data exhibited a shift of laboratories using newer and more sensitive technology such as Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) for screening and confirmation. Overall, data show that laboratories are willing to implement changes to be in compliance with the recommendations; however, challenges with instrument capacity and technology, lack of staffing, training, laboratory space constraints, and time associated with method development and validation hinder compliance with all of the recommendations. While compliance increased, 51% of laboratories reported using the practice of stop-limit testing, an administrative decision to stop testing if a blood alcohol concentration (BAC) result is at or above a certain concentration, which further hinders the understanding of the drug impaired driving problem. THC and/or metabolites remained the most prevalent drug reported by laboratories, followed by stimulants.